RxDoctor Payments Data

Daniel Townsend, MD

Ophthalmology · Boston, MANPI 1003800749

Payments from drug & device makers

$2,861in general payments, 2019–2025

Across 74 payments — averaging $38.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Galderma Laboratories, L.p.$714
  • Aerie Pharmaceuticals, Inc.$235
  • AbbVie$167
  • Merz North America, Inc.$147
  • Tarsus Pharmaceuticals, Inc.$134
  • plus $423 from 8 others

What the payments were for

  • Speaking & faculty fees$45016%
  • Food & beverage$2,41184%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,861 in reported general payments places this provider in the 70th percentile of 653 ophthalmology providers in Massachusetts.

See all ophthalmology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$326,901
Medicare patients
710
Services billed
3,532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina20$13,001
LumiganBimatoprost22$11,523
ErythromycinErythromycin Base478$5,168
Prednisolone Acetate167$4,983
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha451$4,974
TobradexTobramycin/Dexamethasone11$3,227
Timolol Maleate51$2,944
Latanoprost111$1,585
Tobramycin-DexamethasoneTobramycin/Dexamethasone11$488
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat19$485
Brimonidine Tartrate22$426
Cephalexin27$273
Doxycycline Hyclate25$138
Diazepam80$111
Acetaminophen-CodeineAcetaminophen With Codeine33$75

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Lumigan$167$24,52442 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 653 ophthalmology providers in Massachusetts.

Other ophthalmology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →